FGEN: FibroGen Company Aggregate Debts

Symbol and logo of brand FibroGen Inc (FGEN)

Increased sales of roxadustat and progress in new developments support FibroGen, Inc. (FGEN) quotes, while the debt chronology demonstrates credit load dynamics, where the value has stabilized at 0.00. However, US-China trade conflicts create risks for patents. The business currently relies on sales in Asia, remaining dependent on local regulators following failures in a number of trials.

FibroGen, Inc. - FGEN Company Debts (period 07/04/2022 - 01/08/2026)

Analytical breakdowns and data insights for company FibroGen (FGEN)

- price and consensus price forecast:
Price Performance Chart FibroGen Corporation|FGEN - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization FibroGen Corp|FGEN - Total Company Value
- book capitalization data:
Accounting Value of a Share FibroGen|FGEN - Company Book Value|Market Cap to Net Assets Ratio fibrogen.com|FGEN - Company Total Assets
- debt and liquidity data:
Total Debt to Capital FibroGen, Inc.|FGEN - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital FibroGen Inc|FGEN - Company Debts|Debts to Book Value FibroGen Corp
Fundamental company valuation:FGEN (FibroGen Corporation)
Original product of FibroGen Inc

As FibroGen, Inc. (FGEN) expands its hypoxia and fibrosis therapy ecosystem, the company requires significant resources to implement innovative inhibitors into clinical practice. This metric aggregates all borrowed capital, allowing for an assessment of the business's level of credit dependence and the cost of maintaining operational stability. Analyzing the total creditor burden helps investors balance default risks against return potential, determining the safety of investments within the biopharmaceutical sector.

Analysis of competing companies

Aggregate Debt Obligations Haleon Corp (HLN)|Company Aggregate Debts KVUE (Kenvue Inc.)|veronapharma.com - Company Aggregate Debts|Company Debts Jyong Biotech (MENS)|LGND: Aggregate Debt Obligations|AMRX (Amneal Pharmaceuticals Inc) - Company Debts|Perrigo Corp (PRGO) - Company Total Debt|ALVO (Alvotech) - Company Aggregate Debts|Company Aggregate Debts liquidia.com (LQDA)|Galapagos (GLPG) - Company Total Debt|Aggregate Debt Obligations ANIP (ANI Pharmaceuticals Inc)|MNKD: Company Debts|AMPH - Company Cumulative Debt|Company Total Debt Pacira BioSciences PCRX|SPRY - Company Cumulative Indebtedness|Company Aggregate Debts Theravance Biopharma, Inc. TBPH|Aquestive Therapeutics Inc (AQST) - Aggregate Debt Obligations|Company Aggregate Debts SCPH (scPharmaceuticals, Inc.)|Company Cumulative Debt TECX|Tonix Pharmaceuticals (TNXP) - Company Debts|Aggregate Debt Obligations sxtchina.com (SXTC)|Eupraxia Pharmaceuticals Inc. (EPRX) - Company Aggregate Debts|Company Aggregate Indebtedness BioHarvest Sciences, Inc. BHST|Company Aggregate Debts EXOZ (Invizyne Technologies, Inc.)|ORMP - Company Total Debt Obligations|enterabio.com (ENTX) - Company Aggregate Debts|HYFT (ipatherapeutics.com) - Company Debts|ABVC - Company Debts|Aggregate Debt Obligations CPIX|Quantum BioPharma Limited - Company Debts|Company Cumulative Debt Telomir Pharmaceuticals Corp (TELO)|RANI (Rani Therapeutics Holdings, Inc.) - Company Aggregate Debts|Company Total Indebtedness Synergy CHC Corp. SNYR|RLYB (Rallybio Corp.) - Company Aggregate Debts|LEXX: Company Cumulative Debt|Company Debts Pulmatrix Corp|Company Aggregate Debt Pheton Holdings|APM - Company Total Debt|Aggregate Debt Obligations lyratherapeutics.com|IBO (Impact BioMedical) - Company Aggregate Debts|Company Total Debt Obligations TNFA (tnfpharma.com)|YCBD - Company Debts|Company Aggregate Debt PainReform Corp PRFX|CYTO: Company Aggregate Debts|lipella.com (LIPO) - Company Total Debt|OptiNose - Company Total Debt|Pieris Pharmaceuticals Inc (PIRS) - Company Total Debt Obligations|Company Aggregate Debts Procaps Group SA PROC|Company Aggregate Indebtedness Petros Pharma|QLI: Company Aggregate Debts|Company Total Indebtedness acelyrin.com (SLRN)|TFFP: Company Aggregate Debts